Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer.
Saved in:
| Title: | Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer. |
|---|---|
| Authors: | Nguyen TTH; College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, R3E0T5, Canada., Mital S; College of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, R3E0T5, Canada. shweta.mital@umanitoba.ca. |
| Source: | PharmacoEconomics [Pharmacoeconomics] 2025 Mar; Vol. 43 (3), pp. 351-361. Date of Electronic Publication: 2024 Dec 04. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-2027 |
|---|---|
| DOI: | 10.1007/s40273-024-01456-x |
